| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
|
Galsky, Matthew D
|
|
2011
|
12 |
3 |
p. 211-214
4 p.
|
artikel
|
| 2 |
A new combination for advanced multiple myeloma
|
Palumbo, Antonio
|
|
2011
|
12 |
3 |
p. 207-208
2 p.
|
artikel
|
| 3 |
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections
|
Marchini, Sergio
|
|
2011
|
12 |
3 |
p. 273-285
13 p.
|
artikel
|
| 4 |
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
|
Kindler, Hedy L
|
|
2011
|
12 |
3 |
p. 256-262
7 p.
|
artikel
|
| 5 |
Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial
|
Berenson, James
|
|
2011
|
12 |
3 |
p. 225-235
11 p.
|
artikel
|
| 6 |
Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all
|
Harford, Joe B
|
|
2011
|
12 |
3 |
p. 306-312
7 p.
|
artikel
|
| 7 |
Cancer in developing countries: can the revolution begin?
|
The Lancet Oncology,
|
|
2011
|
12 |
3 |
p. 201-
1 p.
|
artikel
|
| 8 |
Can communication technologies reduce inequalities in cancer care?
|
Qaddoumi, Ibrahim
|
|
2011
|
12 |
3 |
p. 224-
1 p.
|
artikel
|
| 9 |
Circulating endothelial cells as biomarkers for patients receiving bevacizumab
|
Bertolini, Francesco
|
|
2011
|
12 |
3 |
p. 217-218
2 p.
|
artikel
|
| 10 |
Development of targeted therapies for pancreatic cancer
|
Philip, Philip A
|
|
2011
|
12 |
3 |
p. 206-207
2 p.
|
artikel
|
| 11 |
Elementary flaws in the FH01 study
|
Jørgensen, Karsten Juhl
|
|
2011
|
12 |
3 |
p. 215-
1 p.
|
artikel
|
| 12 |
Elementary flaws in the FH01 study – Authors' reply
|
Duffy, Stephen W
|
|
2011
|
12 |
3 |
p. 215-216
2 p.
|
artikel
|
| 13 |
Explaining trends in lung cancer deaths in women
|
Senior, Kathryn
|
|
2011
|
12 |
3 |
p. 220-
1 p.
|
artikel
|
| 14 |
HERA crosses over
|
Joensuu, Heikki
|
|
2011
|
12 |
3 |
p. 203-204
2 p.
|
artikel
|
| 15 |
Is oral sex safe?
|
Burki, Talha
|
|
2011
|
12 |
3 |
p. 223-
1 p.
|
artikel
|
| 16 |
Kyphoplasty in cancer: an encouraging step
|
Schiff, David
|
|
2011
|
12 |
3 |
p. 202-203
2 p.
|
artikel
|
| 17 |
microRNAs in stage I epithelial ovarian cancer
|
Wiemer, Erik AC
|
|
2011
|
12 |
3 |
p. 208-209
2 p.
|
artikel
|
| 18 |
Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
|
Bozovic-Spasojevic, Ivana
|
|
2011
|
12 |
3 |
p. 209-211
3 p.
|
artikel
|
| 19 |
New terminology for cytoreduction in advanced ovarian cancer
|
Zapardiel, Ignacio
|
|
2011
|
12 |
3 |
p. 214-
1 p.
|
artikel
|
| 20 |
NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma
|
Griffiths, Christian
|
|
2011
|
12 |
3 |
p. 221-222
2 p.
|
artikel
|
| 21 |
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
|
Mariette, Christophe
|
|
2011
|
12 |
3 |
p. 296-305
10 p.
|
artikel
|
| 22 |
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
|
Cuzick, Jack
|
|
2011
|
12 |
3 |
p. 245-255
11 p.
|
artikel
|
| 23 |
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
|
Leyland-Jones, Brian
|
|
2011
|
12 |
3 |
p. 286-295
10 p.
|
artikel
|
| 24 |
Show us a sign: the search for “game changing” prostate cancer biomarkers
|
Quinn, David
|
|
2011
|
12 |
3 |
p. 204-206
3 p.
|
artikel
|
| 25 |
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
|
Gianni, Luca
|
|
2011
|
12 |
3 |
p. 236-244
9 p.
|
artikel
|
| 26 |
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
|
Ghobrial, Irene M
|
|
2011
|
12 |
3 |
p. 263-272
10 p.
|
artikel
|
| 27 |
Where next for research and development in oncology?
|
Greatrex, Jessica
|
|
2011
|
12 |
3 |
p. 219-220
2 p.
|
artikel
|
| 28 |
10-year analysis of the ATAC trial: wrong conclusion?
|
Tannock, Ian F
|
|
2011
|
12 |
3 |
p. 216-217
2 p.
|
artikel
|
| 29 |
10-year analysis of the ATAC trial: wrong conclusion? – Authors' reply
|
Cuzick, Jack
|
|
2011
|
12 |
3 |
p. 217-
1 p.
|
artikel
|
Tijdschrift beschrijving